Website: University of Ottawa
Dr. Courtman is trained incellular and molecular pathology and biophysics with extensive expertise in the development of novel therapies for cardiovascular disease. He has a long-standing interest in the development of novel cardiovascular biomaterialsand the regulation of biological responses within the unique spatially oriented matricellular environment of blood vessels. He has also participated in the development of a number of cellular based gene therapies for the treatment of cardio-pulmonary disorders taking them from initial concept, through appropriate animal disease models, and into first-in-human clinical trials. DrCourtman is currently directing the manufacturing of these cell products for trials treating patients suffering from pulmonary arterial hypertension, myocardial infarction, and sepsis. He is a Scientist and Direct of Biotherapeutics at the Ottawa Hospital Research Institute, Assistant Professor at the University of Ottawa, and Chief Scientific Officer of Northern Therapeutics.
Recent Stem Cell Publications:
Taljaard M, Ward MR, Kutryk MJ, Courtman DW, Camack NJ, Goodman SG, Parker TG, Dick AJ, Galipeau J, Stewart DJ. Rationale and design of Enhanced Angiogenic Cell Therapy in Acute Myocardial Infarction (ENACT-AMI): the first randomized placebo-controlled trial of enhanced progenitor cell therapy for acute myocardial infarction. Am Heart J. 2010 Mar;159(3):354-60.
Hakimzadeh N, Stewart DJ, Courtman DW. The role of transglutaminase 2 and osteopontin in matrix protein supplemented microencapsulation of marrow stromal cells. Biomaterials 2010 Dec;31(35):9256-65.
Ormiston ML, Deng Y, Stewart DJ, Courtman DW. Innate immunity in the therapeutic actions of endothelial progenitor cells in pulmonary hypertension. Am J Respir Cell Mol Biol. 2010 Nov;43(5):546-54.